Revolution Medicines’ latest Phase 3 pancreatic cancer result pushed the company back into acquisition focus, with reporting that the market valuation and deal appetite shifted after the survival data emerged. The dataset, from the pan-RAS therapy daraxonrasib, was framed by the company as a potential path toward FDA submission following a median survival gain versus standard chemotherapy. The news arrives after a period in which buyout conversations were reported without Phase 3 results in hand. With the readout now available, stakeholders are re-interpreting both the clinical differentiation and the time line for regulatory and commercial follow-through. For investors and partners, the key near-term issue is whether the Phase 3 benefit-risk profile can support an efficient evidence package and how that changes the leverage of larger pharma in any potential transaction. The next step for Revolution is to decide what to do with the survival data in regulatory discussions and communications.